Rep. Dan Crenshaw

Maddy summaryThis bill removes a requirement for ambulatory surgical centers participating in Medicare to report the COVID-19 vaccination status of their healthcare workers. Specifically, it directs the Secretary of Health and Human Services to revise Medicare regulations (42 CFR §§ 416.300-416.330) within 45 days of enactment to eliminate this reporting mandate. The change directly affects ambulatory surgical centers that receive Medicare funding, removing a specific administrative burden related to employee vaccination data. The bill focuses solely on modifying existing reporting rules, with no new funding or program requirements.

Maddy summaryThis bill changes the negotiation period for small-molecule drugs under the federal Drug Price Negotiation Program from 7 years to 11 years, matching the existing 11-year period for biologic drugs. It directly affects drug manufacturers participating in the program by extending the timeframe for price negotiations with the government. The amendment applies to all small-molecule drugs covered under the program, creating a uniform negotiation timeline for both drug types. The change takes effect as if included in the Inflation Reduction Act of 2022.

Maddy summaryHR 6790 establishes National Institutes of Health centers to advance research, early detection, and public awareness of rare kidney diseases, with a focus on rural and underserved communities. It mandates a federal study on genetic testing barriers, treatment patterns, and public awareness for rare kidney diseases affecting disproportionately impacted populations, including barriers to insurance coverage and access to specialists. The bill also funds nephrology training programs to increase specialists serving these communities and requires experiments to delay or prevent the need for dialysis and transplants. Total funding of $7 million is authorized for fiscal years 2024-2028 to support these research, education, and early intervention efforts.

Maddy summaryHR 6465, the PLASMA Act, amends Medicare Part D's discount program to create a specific phase-in for plasma-derived specialty drugs. It directly affects Medicare Part D beneficiaries who use these drugs and reach their annual out-of-pocket spending limit. The bill establishes a new "specified plasma-derived product percent" to calculate discounted prices for these drugs, based on whether beneficiaries have already met their out-of-pocket threshold for other Part D drugs. This changes how manufacturers' negotiated prices are discounted for plasma-derived products under the existing program, without creating new benefits or altering coverage.

Maddy summaryThis bill adds Ecuador to the list of countries eligible for trade benefits under the Caribbean Basin Economic Recovery Act (CBERA), specifically designating it as a "CBTPA beneficiary country" for preferential tariff treatment. It requires the President to issue a formal proclamation designating Ecuador as such within 90 days of the bill's enactment. The change would allow Ecuadorian goods to enter the U.S. with reduced or eliminated tariffs under the CBERA framework, directly affecting Ecuador's exporters and U.S. importers of Ecuadorian products. This is a procedural adjustment to existing trade law, not a new policy.

Maddy summaryThe Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.

Maddy summaryThis bill (HR 5608) allows health insurance issuers in the Affordable Care Act marketplaces to contribute directly to enrollees' health savings accounts (HSAs) instead of reducing cost-sharing (like deductibles) for silver-level high-deductible health plans. It affects individuals enrolled in these specific plans who elect this option, requiring insurers to pay into their HSAs monthly (equal to the cost-sharing reduction they would have received) using a medical-only debit card. Insurers must also offer high-deductible plans as alternatives to standard silver plans and provide public education about this option starting in 2025. The changes apply to months beginning after December 2024, with funds treated as advance payments toward tax credits.

Maddy summaryThe Maintaining Investments in New Innovation Act (HR 5547) extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines an "advanced drug product" as a drug using genetically targeted technology to change how genes work, such as drugs that suppress or activate gene function. The bill amends the Social Security Act to update the definition of "qualifying single source drug" to include these advanced therapies with the longer exclusivity period. This change directly affects drug manufacturers developing such advanced therapies and influences Medicare's drug coverage rules by delaying generic competition for these specific treatments.

Maddy summaryHR 5391 requires drug manufacturers to pay rebates to Medicare when the price of certain high-cost cancer drugs (called "selected drugs") exceeds a negotiated "maximum fair price" (MFP). This applies to Medicare Part B beneficiaries using these specific drugs, lowering their out-of-pocket costs. The bill mandates manufacturers to calculate rebates based on the difference between current Medicare payment rates (ASP+6) and the new MFP-based rates, reducing beneficiary coinsurance from ASP+6 to MFP+6. The rebates are deposited into Medicare's trust fund and apply to drugs already subject to MFP negotiations under existing law.

Maddy summaryThis bill allows employees to directly transfer funds from a health flexible spending account (FSA) or health reimbursement arrangement (HRA) to a health savings account (HSA) when switching to a high-deductible health plan after a gap in coverage. It sets a dollar limit on these transfers based on annual HSA contribution rules and requires the transfer to occur after a significant period without coverage. Employers must report these transfers on employees' W-2 forms. The changes apply to distributions made after December 31, 2023.